These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 1801092)

  • 1. [Primum non nocere: the end of CAST-II. Cardiac Arrhythmia Suppression Trial].
    Farré J; Moro C
    Rev Esp Cardiol; 1991 Dec; 44(10):632-3. PubMed ID: 1801092
    [No Abstract]   [Full Text] [Related]  

  • 2. NHLBI stops arrhythmia study: implantable cardiac defibrillators reduce deaths.
    Circulation; 1997 Jun; 95(11):2465. PubMed ID: 9184572
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cardiac arrhythmia suppression trial (CAST)].
    Furlanello F
    G Ital Cardiol; 1990 Feb; 20(2):171-6. PubMed ID: 2109715
    [No Abstract]   [Full Text] [Related]  

  • 4. [Anti-arrhythmia agents following a myocardial infarct: the results of the CAST study. Cardiac Arrhythmia Suppression Trial].
    Hohnloser S
    Dtsch Med Wochenschr; 1991 Jul; 116(30):1166-7. PubMed ID: 1855450
    [No Abstract]   [Full Text] [Related]  

  • 5. [Cardiac Arrhythmia Suppression Trial: a disappointment?].
    Magalhães CO
    Arq Bras Cardiol; 1990 Sep; 55(3):153-4. PubMed ID: 2095719
    [No Abstract]   [Full Text] [Related]  

  • 6. ECG of the month. Primum non nocere! Ventricular premature impulses.
    Martinez-Lopez JI
    J La State Med Soc; 1991 Dec; 143(12):5, 7-8. PubMed ID: 1779192
    [No Abstract]   [Full Text] [Related]  

  • 7. CAST and beyond. Implications of the cardiac arrhythmia suppression trials. By the Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
    Eur Heart J; 1990 Mar; 11(3):194-9. PubMed ID: 2108031
    [No Abstract]   [Full Text] [Related]  

  • 8. [The variability and prognostic significance of ventricular hyperkinetic arrhythmias in the postinfarct: the considerations after the CAST. Cardiac Arrhythmia Suppression Trial].
    Furlanello F; Gramegna L
    G Ital Cardiol; 1990 Jul; 20(7):615-7. PubMed ID: 2245899
    [No Abstract]   [Full Text] [Related]  

  • 9. [Antiarrhythmic agents: current situation].
    Bonhorst D
    Rev Port Cardiol; 1995 May; 14(5):421-9, 362. PubMed ID: 7654403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The early termination of clinical trials: causes, consequences, and control. With special reference to trials in the field of arrhythmias and sudden death. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
    Eur Heart J; 1994 Jun; 15(6):721-38. PubMed ID: 8088260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fact and fiction--results of the cardiac arrhythmia suppression trial.
    Wyse DG
    Can J Cardiol; 1991; 7(1):51-4; discussion 55-8. PubMed ID: 1902755
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of class III antiarrhythmic agents in maintaining sinus rhythm.
    Brachmann J
    Europace; 2000 Jul; 1 Suppl C():C10-5. PubMed ID: 11220519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of arrhythmias beyond CAST].
    Hertzeanu H; Pines A
    Harefuah; 1991 Nov; 121(10):388-90. PubMed ID: 1752558
    [No Abstract]   [Full Text] [Related]  

  • 14. Amiodarone in high-risk post-infarction patients, Lessons from EMIAT and CAMIAT. European Myocardial Infarct Amiodarone Trial and Canadian Amiodarone Myocardial Infarction Arrhythmia Trial.
    Gambhir DS
    Indian Heart J; 1996; 48(4):339-41. PubMed ID: 8908817
    [No Abstract]   [Full Text] [Related]  

  • 15. [Ventricular arrhythmias: diagnosis and drug therapy].
    Schüpfer C; Gertsch M
    Praxis (Bern 1994); 1996 May; 85(20):647-54. PubMed ID: 8685556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [When is arrhythmia therapy indicated?].
    Gahl K
    MMW Munch Med Wochenschr; 1980 Jan; 122(3):79-80. PubMed ID: 6154234
    [No Abstract]   [Full Text] [Related]  

  • 17. [Possibilities and trends in pharmacotherapy of cardiac arrhythmias in childhood and adolescence. 2: Anti-arrhythmia agents and anti-arrhythmia active drugs in the present and future].
    Mücke D
    Z Arztl Fortbild (Jena); 1988; 82(6):251-4. PubMed ID: 3043927
    [No Abstract]   [Full Text] [Related]  

  • 18. A class III antiarrhythmic agent.
    Pelter MM; Adams MG
    Am J Crit Care; 2002 Jul; 11(4):395-6. PubMed ID: 12102441
    [No Abstract]   [Full Text] [Related]  

  • 19. [Drug treatment of cardiac arrhythmias. II. Mechanism of formation. Clinical and therapeutic aspects].
    Pasini U
    Arq Bras Cardiol; 1970 Apr; 23(2):121-30. PubMed ID: 5523885
    [No Abstract]   [Full Text] [Related]  

  • 20. [What information is given by controlled clinical trials (pharmacological and nonpharmacological) for anti-arrhythmia therapy in the prevention of sudden death?].
    Naccarella F; Croci F
    G Ital Cardiol; 1996 Nov; 26(11):1345-64. PubMed ID: 9036037
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.